CelaneseCE
Recorded

Celanese 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration48 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Greetings, and welcome to Celanese's Q3 2026 earnings call and webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the brief remarks. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference is being recorded. I will now turn the conference over to Bill Cunningham. Thank you, Bill. You may begin.

Bill CunninghamVP of Investor Relations

Thanks, Daryl, and welcome to the Celanese Corporation Third Quarter 2026 Earnings Conference Call. My name is Bill Cunningham, Vice President of Investor Relations. With me today on the call are Scott Richardson, President and Chief Executive Officer, and Chuck Kyrish, Chief Financial Officer. Celanese distributed its third quarter earnings release via Business Wire and posted prepared comments, as well as a presentation on our investor relations website yesterday afternoon. As a reminder, we'll discuss non-GAAP financial measures today. You can find definitions of these measures, as well as reconciliations to the comparable GAAP measures on our website. Today's presentation will also include forward-looking statements. Please review the cautionary language regarding forward-looking statements, which can be found at the end of both the press release and the prepared comments. Form eight-K reports containing all of these materials have also been submitted to the SEC.

Bill CunninghamVP of Investor Relations

With that, Daryl, let's go ahead and open it up for questions.

Operator

Thank you. We'll now be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. We ask that you please limit yourself to one question and one follow-up question. Our first questions are coming from the line of Ghansham Panjabi with Baird. Please proceed with your questions.

Ghansham PanjabiAnalyst

Thank you, operator. Good morning, everybody. I guess first off, in terms of the EBITDA underpinning your $700 million-$800 million free cash flow assumption for next year, can you just give a sense as to what you are assuming in terms of underlying assumptions? Is it basically some version between 2025 and 2026, adjusting for the cost savings? What is your initial view on that?

Scott RichardsonPresident and CEO

Thanks, Ghansham. Let me start, and then I will turn it to Chuck to talk a little bit about how he is thinking about free cash flow generation. The team is really being very intentional about how we engage with customers right now to finish the year, so we can plan and position for what is still some uncertainty as we go into 2027. I think Acetyl Chain continues to focus on contracting business, and with some of the benefits that we have seen from the reliability of supply, getting that business contracted for 2027, and Engineered Materials being really deliberate and intentional with how we build the pipeline with high quality, particularly in some of these growth segments.

Scott RichardsonPresident and CEO

I think with that, when you combine that focus of top line with the cost actions that we called out, pushing approximately $100 million between cost and interest next year, we do feel like we can make 2026 a base that we can build off of going into 2027.

Chuck KyrishCFO

Thanks. Ghansham, look, I think we are demonstrating our capability to generate $700 million-$800 million of free cash flow in two very different environments the last couple of years, right? As the last couple years, there is a few different scenarios that we can hit that. It is either the earnings or some leverage that we have on working capital. So, we are confident in this $700 million-$800 million range for next year. A little bit more context, I think to start, there is really no need to increase our CapEx.

Chuck KyrishCFO

are very targeted growth areas. Going forward into 2027 from 2026, there is still a lot of opportunity in working capital because if you look at our inventory values, I mean, they are still elevated, and we still have structural opportunities there as well. In addition, I would point out that at Celanese, it is productivity every day, but a lot of the large cost savings programs that needed large cash outlays, they are kind of running their course, right? So, that cash outlay for restructuring activities should continue to decline next year. Call that $30 million-$40 million, right? So, all those things considered, Ghansham, we feel that $700 million-$800 million is really the right range for next year.

Ghansham PanjabiAnalyst

Perfect. Just for my second question, on the electronics and healthcare piece, obviously, that has had substantial growth, and profit mix is clearly quite favorable, and that is some of the offset towards perhaps auto OEM and some of the mix backdrop there, the forecasters are calling out in terms of bills, et cetera, certainly for 4Q. But as we think about 2027, you are going to have tougher comps for those two verticals. Just your thoughts as it relates to the momentum on the sales side for both electronics and healthcare into 2027 would be helpful.

Scott RichardsonPresident and CEO

Thank you. Yeah. Our EM team is staying very close to customers right now.

Scott RichardsonPresident and CEO

Staying close to customers and matching our capabilities that we have, which we believe are immense, with the opportunity sets that are out there. It really is a focus on quality, and quality into the pipeline, and moving that through as quickly as possible to get to commercialization. When you look at electronics and medical, we still see tailwind going into next year, Ghansham, and we do not think that that stops. Certainly, we are working many different end-use areas, and we continue to partner with customers on some really interesting new development programs, really across every end use that we have. But certainly, medical and electronics has been a bright spot for us this year, and we expect that to continue into 2027.

Ghansham PanjabiAnalyst

Okay, perfect. Thanks so much.

Operator

Thank you. Our next question is coming from the line of Patrick Cunningham with Citi. Please proceed with your questions.

Patrick CunninghamAnalyst

Hi, good morning. Thanks for taking my questions. Really compelling slide on the margin contribution from downstream derivatives in the Western Hemisphere. Do you need to build any more capacity there, if you have any line of sight into North America building and construction demands? I am just curious, on the downstream capacity specifically, how would you assess the risk longer term of those businesses being disrupted by Asian supply?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day